111 related articles for article (PubMed ID: 38725010)
1. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract][Full Text] [Related]
2. Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
Zhang N; Shao JB; Li H; Yang JW; Chen K; Zhu JS; Jiang H
World J Pediatr; 2020 Apr; 16(2):152-158. PubMed ID: 31748985
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
[TBL] [Abstract][Full Text] [Related]
4. Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
Jin M; Hu Y; Wu W; Luo Y; Tan Y; Yu J; Jin A; Yang L; Huang H; Wei G
BMC Cancer; 2019 Mar; 19(1):242. PubMed ID: 30885156
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
7. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Duan MH; Zhang Y; Zhang M; Han X; Zhang Y; Yang C; Feng J; Zhang L; Zhang W; Li J; Tian LP; Zhang Y; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):571-5. PubMed ID: 27535856
[TBL] [Abstract][Full Text] [Related]
9. Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
Cao S; Tao Q; Wang J; Zhang Q; Dong Y
Medicine (Baltimore); 2023 Nov; 102(44):e34949. PubMed ID: 37933074
[TBL] [Abstract][Full Text] [Related]
10. Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.
Zhang J; Sun Y; Zhang X; Long B; Lu Y; Li X
Transplant Proc; 2018; 50(1):246-249. PubMed ID: 29407318
[TBL] [Abstract][Full Text] [Related]
11. [CLAG Regimen Composed of Continuous Intravenous Infusion of Cladribine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
Mi RH; Chen L; Yang HP; Wang XJ; Guo SL; Shi L; Yin QS; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):333-338. PubMed ID: 33812396
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Wang L; Xu J; Tian X; Lv T; Yuan G
Acta Haematol; 2019; 141(1):43-53. PubMed ID: 30517910
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
14. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
15. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
16. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
Palmieri R; Buckley SA; Othus M; Halpern AB; Percival MM; Scott BL; Hendrie PC; Becker PS; Oehler VG; Estey EH; Walter RB
Leuk Lymphoma; 2020 Jul; 61(7):1728-1731. PubMed ID: 32077361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
